From: Phase 1 study of TRU-015, a CD20-directed small modular immunopharmaceutical (SMIP™) protein therapeutic, in subjects with rheumatoid arthritis
Group (mg/kg)
Area under the curve from time 0 to infinity (μg/h/ml)
Maximum concentration of drug (μg/ml)
Half-life (hours)
Coefficient of variability (%)
0.5
1,342
13.8
281
59.1
1.5
7,082
58.2
282
26.5
5
18,140
154
295
33.4
15
71,753
462
409
32.8